Cellectis draws down second tranche under EIB credit facility [Seeking Alpha]
Cellectis S.A. - American Depositary Shares (CLLS)
Last cellectis s.a. - american depositary shares earnings: 3/4 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
cellectis.com/en/investors
Company Research
Source: Seeking Alpha
The biotech said the agreement is for up to EUR 40M and was entered into in December 2022. The second tranche is expected to be disbursed by Jan. 25. As a condition of the disbursement, Cellectis issued 1.46M warrants to the benefit of the EIB, the company said in a statement . Each warrant allows the EIB to subscribe for one ordinary share at an exercise price of EUR 2.53. The EIB agreement allows the company to draw down a third tranche of up to EUR 5M, subject to certain conditions. Cellectis plans to use proceeds from the second tranche for development of its allogeneic Car T cell product candidates UCART22, UCART20x22 and UCART 123. Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
CLLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLLS alerts
High impacting Cellectis S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CLLS
News
- Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs [Yahoo! Finance]Yahoo! Finance
- Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsGlobeNewswire
- SmartCella strengthens team with Dr Ricardo Baptista as CTO [Yahoo! Finance]Yahoo! Finance
- Cellectis S.A. (NASDAQ: CLLS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs [Yahoo! Finance]Yahoo! Finance
CLLS
Earnings
- 11/6/23 - In-Line
CLLS
Sec Filings
- 4/22/24 - Form 6-K
- 4/10/24 - Form 6-K
- 4/8/24 - Form 6-K
- CLLS's page on the SEC website